Találati lista | Tudóstér

001-es BibID:	BIBFORM045382
035-os BibID:	PMID:21153723
Első szerző:	Horváth Zsolt (onkológus, belgyógyász, klinikai farmakológus)
Cím:	Inflammatory breast cancer - comparing the effectivity of preoperative docetaxel-epirubicine protocol to conventional antracycline-containing chemotherapy to achieve clinical benefit and complete pathological response / Zsolt Horváth, László Torday, Erika Hitre, Erna Ganofszky, Éva Juhos, Ferenc Czeglédi, László Urbán, Csaba Polgár, István Láng, Sándor Eckhardt, Miklós Kásler
Dátum:	2011
ISSN:	1219-4956 1532-2807
Megjegyzések:	Our retrospective analysis compared the effectiveness of conventional antracycline-containing protocols (A+) and docetaxel/epirubicine (TE) as primary systemic chemotherapies (PSCT) for inflammatory breast cancer (IBC). Seventy IBC patients received either A?+?(n?=?48) or TE (n?=?22) as PSCT. The objective clinical response and clinical benefit rate of treated patients were 54.3% (A+: 54,2% vs. TE: 54,5%; p = 0,28) and 92.8% (A+: 91,7% vs. TE: 95,5%; p = 0,57), respectively. The clinical complete response rate (cCR) was 23.2% (A+: 27,1% vs. TE:4,5%; ? (2)?=?4,79; p = 0,03) with 7.14% (A+: 10,4% vs. TE:0%; ? (2)?=?2,47; p?=?0,12) of pathological complete responses (pCR). The median progression free (PFS)/local progression free (LPFS)/overall survival (OS) was 2.0/5.4/4.0 years, respectively. Patients achieving cCR had a tendency for better survival parameters than patients with less than cCR. Response rates or survival data were not statistically different in the two chemotherapy (CT) treatment groups. The survival was not influenced by the number of CT cycles in either protocols. In this set of patients, the clinical efficacy of the two alternative primary systemic chemotherapies (A?+?and TE) is equivalent in the treatment of inflammatory breast cancer (IBC), despite of the significant difference in favour of A?+?noticed in CRs. Six cycles of CT could be enough for patients achieving CR, however sequential pre- and/or postoperative CT with non cross-resistant drugs should be considered for non-responders.
Tárgyszavak:	Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban Anthracycline Docetaxel Inflammatory breast cancer Pathological complete remission Primary systemic chemotherapy
Megjelenés:	Pathology & Oncology Research. - 17 : 3 (2011), p. 541-550. -
További szerzők:	Torday László Hitre Erika Ganofszky Erna Juhos Éva (onkológus) Czeglédi Ferenc Urbán László (1960-) Polgár Csaba Láng István Eckhardt Sándor Kásler Miklós
Internet cím:	Szerző által megadott URL DOI Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Saját polcon: